Statement 7: In my clinical practice, I consider that the polymorphisms in the FSH and/or the beta variant of LH, could increase the risk of low response in patients with associated risk factors (advanced age, diabetes, obesity, chronic illness...). Here, PLOD1 is linked to obesity disorder.